Hematopoietic Stem Cell Transplantation - Epidemiology Forecast - 2032

This ‘Hematopoietic Stem Cell Transplantation (HSCT) Overview - Epidemiology Forecast-2032' report delivers an in-depth understanding of the HSCT historical and forecasted epidemiology as well as the HSCT epidemiology trends in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

Hematopoietic Stem Cell Transplantation (HSCT) Understanding

Hematopoietic Stem Cell Transplantation (HSCT) Overview

Hematopoietic stem cell transplantation (HSCT) administers healthy hematopoietic stem cells (HSC) to patients with defective or depleted bone marrow. This improves bone marrow function and, depending on the disease being treated, leads to either the destruction of malignant tumor cells or the generation of functional cells that can replace the dysfunctional ones, as in the case of immune-deficiency syndromes, hemoglobinopathies, and other diseases. HSCs are immature blood cells found in the peripheral blood and the bone marrow. These are also called blood stem cells. These are produced in the bone marrow and can develop into any type of blood cell required by the body. Stem cells divide and mature, replacing older and worn-out blood cells.

Hematopoietic Stem Cell Transplantation (HSCT) Procedure

The procedure of HSCT includes donor matching, mobilization, harvesting, conditioning, and infusion. The selection of a donor is an essential factor in the success of hematopoietic cell transplantation. There are many possible choices for an allogeneic HSC donor, which are as follows:

• Matched donor - A donor with a comparable genetic makeup to the patient is preferable to assist or limit the issues that the expected immunological reaction might create. Siblings are usually the only members of the family. They may be matched entirely at the critical genes known as the human leukocyte antigen or HLA genes, which are proteins located on cellular surfaces.
• Matched unrelated donor - If no siblings are available, testing their blood does not indicate a match or sibling donors are deemed unsuitable, a matched unrelated donor may be utilized. The search for a suitable donor can be carried out utilizing transplant registries worldwide.

Hematopoietic Stem Cell Transplantation (HSCT) Indications

Indications for HSCT have been bifurcated into malignant and nonmalignant diseases.

• Malignant disease
• Multiple Myeloma - Studies have shown increased overall survival and progression-free survival in patients younger than 65 when consolidation therapy with melphalan is initiated, followed by ASCT and lenalidomide maintenance therapy. The study showed a favorable outcome of high-dose melphalan plus stem-cell transplantation compared with consolidation therapy with melphalan, prednisone, and lenalidomide (MPR). It also showed a better outcome in patients who received maintenance therapy with lenalidomide.
• Hodgkin and Non-Hodgkin Lymphoma - Studies have shown that chemotherapy followed by ASCT in cases of recurrent lymphomas (HL and NHL) that do not respond to conventional chemotherapy has better outcomes. A randomized controlled trial by Schmitz et al. showed a better 3-year outcome of high-dose chemotherapy with ASCT compared to aggressive conventional chemotherapy in relapsed chemo sensitive Hodgkin lymphoma. However, the overall survival was not significantly different between the two groups. The number of hematopoietic SCT recipients comes second after multiple myeloma, according to CIBMTR.

Hematopoietic Stem Cell Transplantation (HSCT) Epidemiology Perspective

The epidemiology covered in the report provides historical as well as forecasted epidemiology segmented by Total Cases of Hematopoietic Stem Cell Transplantation, Type-specific Cases of Hematopoietic Stem Cell Transplantation, and Total Cases of Hematopoietic Stem Cell Transplantation by Indication scenario in the 7MM covering the United States, EU-5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan from 2019 to 2032.

Hematopoietic Stem Cell Transplantation (HSCT) Detailed Epidemiology Segmentation

• In 2021, the total cases of HSCT in the 7MM countries were 55,999, and these cases are anticipated to increase during the study period. The US accounted for 23,971 cases of HSCT in 2021.
• Among the European countries, Germany had the highest number of cases of HSCT in 2021, i.e., 7,085 cases, followed by Italy which had 5,625 cases in 2021. On the other hand, Spain had the lowest number of cases of HSCT, i.e. 3,439 cases in 2021.
• In terms of type-specific cases of HSCT, the percentage of autologous HSCT cases is more in comparison to allogeneic HSCT across the 7MM except for Japan.
• Japan, in 2021, accounted for 5,872 cases of HSCT, which is expected to increase during the study period.
• In terms of indications for HSCT, multiple myeloma/plasma cell disorders bags the largest pool among all the considered indications in the 7MM except for Japan

Scope of the Report

• The report covers a descriptive overview of HSCT, explaining its procedure, types, indications, and currently available therapies.
• The report provides insight into the 7MM historical and forecasted patient pool covering the United States, EU-5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
• The report assesses the HSCT risk and burden.
• The report provides the segmentation of the epidemiology for 7MM by segmented by ‘Total Cases of Hematopoietic Stem Cell Transplantation, Type-specific Cases of Hematopoietic Stem Cell Transplantation, and Total Cases of Hematopoietic Stem Cell Transplantation by Indication'.

Report Highlights

• 11-Year Forecast of Hematopoietic Stem Cell Transplantation
• 7MM Coverage
• Total Cases of Hematopoietic Stem Cell Transplantation
• Type-specific Cases of Hematopoietic Stem Cell Transplantation
• Total Cases of Hematopoietic Stem Cell Transplantation by Indication

Key Questions Answered

• What are the risk, burdens, and unmet needs of HSCT?
• What is the historical HSCT patient pool in the United States, EU-5 (Germany, France, Italy, Spain, and the UK), and Japan?
• What would be the forecasted patient pool of HSCT at the 7MM level?
• What will be the growth opportunities across the 7MM with respect to the patient population pertaining to HSCT?
• Out of the countries mentioned above, which country would have the highest cases of HSCT during the forecast period (2022-2032)?
• At what CAGR the population is expected to grow across the 7MM during the forecast period (2022-2032)?

Reasons to Buy

The HSCT report will allow the user to -

• Develop business strategies by understanding the trends, shaping and driving the 7MM HSCT epidemiology.
• The HSCT epidemiology report and model were written and developed by Masters and PhD level epidemiologists.
• The HSCT epidemiology model developed by the publisher is easy to navigate, interactive with dashboards, and epidemiology based on transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over the 11-year forecast period using reputable sources.

Geographies Covered

• The United States
• EU-5 (Germany, France, Italy, Spain, and the United Kingdom)
• Japan

Study Period: 2019-2032